$0.5205
-0.0257-4.71%
Last update: Nov 10, 4:18 PM
60 Degrees Pharmaceuticals Inc
SXTPNASDAQ
60 Degrees Pharmaceuticals fell 89.8% from $5.12 to $0.52, behind the S&P 500's +10.0%. Its worst day was Nov 6 (−33.3%), and its low came Nov 10 at $0.52.
Nov 10, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-2.64 beat the $-3.04 estimate on $437,602.00 revenue (est. $242,000.00).
−4.9% · S&P 500 −1.7%
60 Degrees Pharmaceuticals closed at its highest level of the year, 1.6% above where the year started.
Story events cover the past 12 months · Times ET
+7.9% · S&P 500 0.0%
All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing babesiosis treatment
+71.3% · S&P 500 −0.1%
EPS of $-1.47 beat the $-2.11 estimate on $303,385.00 revenue (est. $537,000.00).
+15.9% · S&P 500 +2.9%
EPS of $-1.28 missed the $-0.94 estimate on $76,377.00 revenue (est. $436,000.00).
−4.8% · S&P 500 −1.2%
EPS of $-0.90 missed the $-0.86 estimate on $56,798.00 revenue (est. $186,000.00).
+1.3% · S&P 500 −0.2%
Where it ended: a close of $0.52 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.83, revenue est. $276,000.00).
Nothing in the past 12 months.
All SXTP dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SXTP and SPY from Benzinga historical bars. Not investment advice.
